Clinical trial
IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After…
NCT00242788 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00242788 |
|---|---|
| Title | IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure |
| Official title | A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib and capecitabine |
| Enrollment | 40 |
| Start date | Feb 1, 2004 |
| Completion | Nov 1, 2005 |
| First posted | Oct 21, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: